Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

达帕格列嗪 二甲双胍 医学 2型糖尿病 安慰剂 糖尿病 内科学 临床终点 胰岛素 内分泌学 随机对照试验 替代医学 病理
作者
Clifford J. Bailey,Jorge Luiz Gross,Anne Pieters,Arnaud Bastien,James F. List
出处
期刊:The Lancet [Elsevier BV]
卷期号:375 (9733): 2223-2233 被引量:857
标识
DOI:10.1016/s0140-6736(10)60407-2
摘要

Background Correction of hyperglycaemia and prevention of glucotoxicity are important objectives in the management of type 2 diabetes. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption in an insulin-independent manner. We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin. Methods In this phase 3, multicentre, double-blind, parallel-group, placebo-controlled trial, 546 adults with type 2 diabetes who were receiving daily metformin (≥1500 mg per day) and had inadequate glycaemic control were randomly assigned to receive one of three doses of dapagliflozin (2·5 mg, n=137; 5 mg, n=137; or 10 mg, n=135) or placebo (n=137) orally once daily. Randomisation was computer generated and stratified by site, implemented with a central, telephone-based interactive voice response system. Patients continued to receive their pre-study metformin dosing. The primary outcome was change from baseline in haemoglobin A1c(HbA1c) at 24 weeks. All randomised patients who received at least one dose of double-blind study medication and who had both a baseline and at least one post-baseline measurement (last observation carried forward) were included in the analysis. Data were analysed by use of ANCOVA models. This trial is registered with ClinicalTrials.gov, number NCT00528879. Findings 534 patients were included in analysis of the primary endpoint (dapagliflozin 2·5 mg, n=135; dapagliflozin 5 mg, n=133; dapagliflozin 10 mg, n=132; placebo, n=134). At week 24, mean HbA1c had decreased by −0·30% (95% CI −0·44 to −0·16) in the placebo group, compared with −0·67% (−0·81 to −0·53, p=0·0002) in the dapagliflozin 2·5 mg group, −0·70% (−0·85 to −0·56, p<0·0001) in the dapagliflozin 5 mg group, and −0·84% (−0·98 to −0·70, p<0·0001) in the dapagliflozin 10 mg group. Symptoms of hypoglycaemia occurred in similar proportions of patients in the dapagliflozin (2–4%) and placebo groups (3%). Signs, symptoms, and other reports suggestive of genital infections were more frequent in the dapagliflozin groups (2·5 mg, 11 patients [8%]; 5 mg, 18 [13%]; 10 mg, 12 [9%]) than in the placebo group (seven [5%]). 17 patients had serious adverse events (four in each of the dapagliflozin groups and five in the placebo group). Interpretation Addition of dapagliflozin to metformin provides a new therapeutic option for treatment of type 2 diabetes in patients who have inadequate glycaemic control with metformin alone. Funding Bristol-Myers Squibb and AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
轩辕十四完成签到,获得积分10
1秒前
斯文败类的应助被Akiba采纳,获得10
1秒前
岳志伟关注了科研通微信公众号
2秒前
斯文败类的应助被Joehq_1203采纳,获得10
2秒前
3秒前
3秒前
3秒前
3秒前
Nole的应助被今天没有哭鸭采纳,获得10
3秒前
Maestro_S的应助被shaco采纳,获得10
3秒前
lili完成签到,获得积分10
3秒前
脑洞疼的应助被15331970326采纳,获得10
4秒前
无极微光的应助被zhoudongxue采纳,获得20
4秒前
5秒前
朱晖发布了新的文献求助20
5秒前
今夜略闲发布了新的文献求助10
5秒前
5秒前
喔喔佳佳L发布了新的文献求助20
5秒前
入司的应助被李麟采纳,获得10
5秒前
Akim的应助被刘泽楷采纳,获得10
6秒前
英姑的应助被楠楠采纳,获得10
6秒前
6秒前
orixero的应助被annona采纳,获得30
6秒前
6秒前
7秒前
瘦瘦大米发布了新的文献求助10
7秒前
月亮完成签到,获得积分10
7秒前
Lucas的应助被Kyra采纳,获得10
7秒前
8秒前
搜集达人的应助被DW采纳,获得30
8秒前
9秒前
何文鑫发布了新的文献求助10
10秒前
刘锰发布了新的文献求助10
11秒前
11秒前
12秒前
迷路芝麻完成签到,获得积分10
12秒前
顾矜的应助被Blue灬boy采纳,获得10
13秒前
爆米花的应助被nana采纳,获得10
13秒前
13秒前
syvshc的应助被Elsevier大王采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139